C069P: Brolucizumab Biosimilar, Anti-human VEGFA Monoclonal Antibody

Catalog No.: C069P | **Product Name:** Brolucizumab Biosimilar, VEGF-A Monoclonal Antibody

Brolucizumab Biosimilar, VEGF-A Monoclonal Antibody. The research grade Brolucizumab biosimilar protein is for research use only (RUO). Recombinant human IgG1 isotype controls are available. Condition of sample preparation and optimal sample dilution should be determined experimentally by the investigator.

PRODUCT SPECIFICATIONS

Catalog No.	C069P
Product Name	Brolucizumab Biosimilar, VEGF-A Monoclonal Antibody
Supplier Name	Syd Labs, Inc.
Brand Name	Syd Labs
Synonyms	VEGF, VEGF-A, vascular endothelial growth factor A
Summary	Recombinant Humanized IgG1 Monoclonal Antibody.
Isotype	Humanized IgG1.
Source/Host	The anti-human vascular endothelial growth factor A (VEGF-A) monoclonal antibody brolucizumab biosimilar was produced in mammalian cells.
Specificity/Sensitivity	The research grade brolucizumab biosimilar specifically binds to the human vascular endothelial growth factor A (VEGF-A).
Applications	ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by brolucizumab.
Form Of Antibody	0.2 μM filtered solution, pH 7.4, no stabilizers or preservatives.
Endotoxin	<1 EU/mg of the protein by the LAL method.
Purity	>95% by SDS-PAGE under reducing conditions and HPLC.
Shipping	The research grade brolucizumab biosimilar is shipped with ice pack. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage	Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70°C as supplied. 1 month from date of receipt, 2 to 8°C as supplied.
Note	The research grade Brolucizumab biosimilar protein is for research use only (RUO). Recombinant human IgG1 isotype controls are available. Condition of sample preparation and optimal sample dilution should be determined experimentally by the investigator.

REFERENCES & BACKGROUND

What is Brolucizumab biosimilar research grade? Brolucizumab Biosimilar uses the same protein sequences as the therapeutic antibody brolucizumab. Brolucizumab is a monoclonal antibody indicated to treat neovascular age related macular degeneration. Brolucizumab is a vascular endothelial growth factor (VEGF) inhibitor which targets the major VEGF-A isoforms: VEGF110, VEGF121, and VEGF165. Inhibition of these VEGF-A isoforms reduce proliferation of endothelial cells, vascularization of the tissue, and permeability of the vasculature.